A Randomized, Double-Blind, 6-Way Crossover Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Lemborexant (Primary) ; Suvorexant; Zolpidem
- Indications Insomnia
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 18 Sep 2017 Planned End Date changed from 1 Nov 2017 to 1 Jan 2018.
- 18 Sep 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
- 25 Jun 2017 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.